Angiogenesis Affecting Patents (Class 514/13.3)
-
Patent number: 11760792Abstract: The present invention relates to a GRP78-derived peptide for screening highly efficient stem cells and the use thereof, and more particularly, to screening highly efficient stem cells using, as a marker, a GRP78-derived peptide capable of binding to the binding domain of GRP78 protein on the cell surface. According to the present invention, the GRP78-derived peptide comprising only a specific amino acid sequence capable of recognizing highly efficient stem cells, among the amino acid sequence of GRP78, makes it possible to screen only non-senescent young stem cells. In addition, when stem cells are treated with the GRP78-derived peptide or the GRP78-derived peptide is introduced into stem cells, the efficiency of the stem cells can be increased. Thus, the GRP78-derived peptide is useful for the production of stem cell therapy products having excellent efficacy.Type: GrantFiled: October 15, 2018Date of Patent: September 19, 2023Assignees: NIBEC CO., LTD., CHUNGBUK NATIONAL UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION, SEOUL NATIONAL UNIVERSITY R&DB FOUNDATIONInventors: Yoon Shin Park, Yoon Jeong Park, Chong-Pyoung Chung, Jue-Yeon Lee
-
Patent number: 11674959Abstract: The present invention in various aspects and embodiments involves pharmaceutical compositions prepared by contacting a candidate ?- or ?-integrin-binding molecule, or panel thereof, with an integrin heterodimer, and quantifying heterodimer disruption by the candidate molecule. An integrin-binding molecule, or derivative thereof, that disrupts the integrin heterodimer is selected and is formulated into a pharmaceutical composition for administration to a subject, e.g., who has a disease or disorder related to abnormal vascularization.Type: GrantFiled: August 3, 2018Date of Patent: June 13, 2023Assignees: The Johns Hopkins University, AsclepiX Therapeutics, Inc.Inventors: Niranjan Pandey, Aleksander S. Popel, Jordan J. Green, Adam Mirando
-
Patent number: 11261237Abstract: Disclosed are modified pigment epithelium-derived factor (PEDF) peptides, particulate carrier prodrugs thereof, and pharmaceutical compositions comprising the peptides or particulate carrier prodrugs. The peptides, particulate carrier prodrugs, and pharmaceutical compositions may be used to treat diseases and disorders that are amenable to treatment with anti-angiogenic agents, anti-tumorigenic agents, anti-fibrotic agents, chemotherapy-protecting agents, and immune stimulating agents.Type: GrantFiled: September 6, 2018Date of Patent: March 1, 2022Assignees: Northwestern University, Board of Regents of the University of NebraskaInventors: Jack Henkin, Olga Volpert, Serguei Vinogradov, Ignacio Melgar-Asensio
-
Patent number: 11229662Abstract: The present subject matter provides compositions, formulations, and methods for inhibiting, treating, or preventing aberrant angiogenesis in a subject.Type: GrantFiled: November 14, 2017Date of Patent: January 25, 2022Assignee: The Schepens Eye Research Institute, Inc.Inventors: Joseph F. Arboleda-Velasquez, Leo A. Kim, Patricia A. D'Amore
-
Patent number: 11207387Abstract: The present invention relates to a method for preventing and/or treating overweight/obesity and their related conditions, comprising administering an effective amount of plasminogen to a subject susceptible to or suffering from obesity and its related conditions, to reduce an abnormal/excessive fat deposition at various sites of the body. The present invention further relates to a medicament for preventing and/or treating obesity, and its use in the preparation of a medicament.Type: GrantFiled: December 15, 2017Date of Patent: December 28, 2021Assignee: TALENGEN INTERNATIONAL LIMITEDInventor: Jinan Li
-
Patent number: 11072636Abstract: Peptide having an angiogenesis inhibitory activity and a use of the peptide, related to the treatment or prevention of excessive angiogenesis-related diseases. Particularly, a novel peptide that binds, in competition with vascular endothelial growth factors (VEGF), to VEGF receptors and can significantly inhibit the proliferation, migration and differentiation of vascular endothelial cells, thereby being effectively usable as an active ingredient of a composition or a health functional food for preventing or treating diseases, such as macular degeneration, a tumor, arthritis or psoriasis, caused by excessive angiogenesis.Type: GrantFiled: March 14, 2018Date of Patent: July 27, 2021Assignee: CAREGEN CO., LTD.Inventors: Yong Ji Chung, Eun Mi Kim, Eung Ji Lee
-
Patent number: 11052079Abstract: The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.Type: GrantFiled: July 31, 2017Date of Patent: July 6, 2021Inventors: Keelung Hong, Daryl C. Drummond, Dmitri Kirpotin
-
Patent number: 10946060Abstract: The present invention relates to a pharmaceutical composition containing ATPase inhibitor factor 1 (ATPIF1) as an active ingredient for the prevention or treatment of diabetes or diabetic complications, and to a pharmaceutical composition containing ATP1F1 as an active ingredient for prevention or treatment of obesity. The composition containing ATPIF1, according to the present invention, has a diabetes treatment effect by promoting sugar absorption in muscle cells and improving insulin sensitivity, and has an obesity prevention or treatment effect by effects of suppressing fat synthesis in fat cells and promoting the browning of fat cells.Type: GrantFiled: March 13, 2018Date of Patent: March 16, 2021Assignee: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATIONInventor: Hyeon Soo Kim
-
Patent number: 10912325Abstract: The present invention relates to a tablet and a method for stabilizing and reversing the effects of age and activity related inflammation in persons over the age of 18.Type: GrantFiled: November 4, 2019Date of Patent: February 9, 2021Inventor: Timothy Chrisman
-
Patent number: 10869938Abstract: A method of determining the amount of intracellular manganese in the myocardium of an individual pre-administered with a manganese contrast agent, or a pharmaceutically acceptable salt thereof, comprising subjecting, the individual to a MRI procedure to assess the signal intensity (SI) of images, or more preferably the longitudinal relaxation rate, R1 throughout the myocardium.Type: GrantFiled: January 18, 2008Date of Patent: December 22, 2020Assignee: 1C TARGETS ASInventors: Per Jynge, Arne Skjold, Henrik W. Larsson
-
Patent number: 10870679Abstract: The invention describes peptide ligands specific for human plasma Kallikrein.Type: GrantFiled: June 20, 2018Date of Patent: December 22, 2020Assignee: BicycleRD LimitedInventors: Daniel Paul Teufel, Catherine Stace, Edward Walker, John Tite
-
Patent number: 10870708Abstract: In one aspect, the present invention provides methods for preventing, treating, reverting and/or delaying angiogenesis in a mammalian subject suffering from, or at risk for developing, an angiogenesis-dependent disease or condition, comprising administering to the subject an amount of a MASP-2 inhibitory agent effective to inhibit angiogenesis. In some embodiments of these aspects of the invention, the MASP-2 inhibitory agent is a MASP-2 antibody or fragment thereof.Type: GrantFiled: March 31, 2017Date of Patent: December 22, 2020Assignee: University of LeicesterInventors: Gregory A. Demopulos, Hans-Wilhelm Schwaeble, Thomas Dudler, Larry Tjoelker
-
Patent number: 10543270Abstract: The present disclosure provides a method of treating wound healing in a subject, the method comprising administering to the subject a compound that inhibits VEGF-B signalling.Type: GrantFiled: December 18, 2014Date of Patent: January 28, 2020Assignees: CSL LIMITED, B-CREATIVE SWEDEN ABInventors: Ulf Eriksson, Annelie Falkevall, Annika Mehlem
-
Patent number: 10512673Abstract: The invention provides a method of treating pathogenic bacterial infection (e.g., tuberculosis infection) in an animal comprising administering a peptide-based inhibitor of the STAT3-IL10 pathway or a nucleic acid encoding the peptide-based inhibitor to the animal. The invention also provides methods of treating chronic granulomatous disease and Wegener's granulomatosis in an animal comprising administering a peptide-based inhibitor of the STAT3-IL10 pathway or a nucleic acid encoding the peptide-based inhibitor to the animal.Type: GrantFiled: January 7, 2016Date of Patent: December 24, 2019Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Colorado State University Research FoundationInventors: Nadya I. Tarasova, Mercedes Gonzalez-Juarrero
-
Patent number: 10357549Abstract: The present invention provides compositions and methods for differentiating a stem cell into an osteoblast or osteoblast progenitor cell. In certain embodiments, the invention may be used for promoting bone formation and increasing bone mass. In one embodiment, the composition comprises an agent which increases PEDF expression, PEDF activity, or both. In one embodiment, the composition comprises full-length PEDF. In one embodiment, the composition comprises a PEDF fragment or PEDF-derived peptide.Type: GrantFiled: July 23, 2015Date of Patent: July 23, 2019Assignee: YALE UNIVERSITYInventor: Chuhan Chung
-
Patent number: 10351613Abstract: The present invention provides peptides for inhibiting tumor, which are fragments of the N terminus of endostatin, having 45 or less amino acid residues, and which at least contain amino acid residues 1-20 of the N terminus, wherein amino acid residues at positions 2 to 18 of the N terminus of endostatin are shown in the disclosure, and the peptides optionally contain mutations at positions 17 and 20-22 as disclosed in the disclosure. The present invention also relates to the coding sequences of the peptides, expression vectors containing the coding sequence, pharmaceutical compositions comprising the peptide, and use of the peptide and pharmaceutical composition in the inhibition, prevention or treatment of tumor.Type: GrantFiled: July 21, 2016Date of Patent: July 16, 2019Assignee: G-Bio Pharma Tech Co., Ltd.Inventor: Hongli Liu
-
Patent number: 10286032Abstract: Described have herein are peptide analogs of a prominin-1 peptide, DRVQRQTTTVVA (SEQ. ID. NO:1) which have enhanced regenerative and/or angiogenesis activity, increase VEGF binding to endothelial cells, and/or increase wound healing activity relative to the peptide of SEQ ID NO: 1. Provided herein are fusion proteins and compositions comprising these peptide analogs and uses thereof.Type: GrantFiled: June 22, 2015Date of Patent: May 14, 2019Assignee: Children's Medical Center CorporationInventors: Avner Adini, Robert D'Amato
-
Patent number: 10246711Abstract: The present disclosure provides for methods of treating or preventing a cardiovascular disorder and/or a related pulmonary disorder in a subject. In certain embodiments, a therapeutically effective amount of a polynucleotide inhibitor of Glucose-6-phosphate dehydrogenase (G6PD) or a nucleic acid encoding G6PD is administered.Type: GrantFiled: November 15, 2017Date of Patent: April 2, 2019Inventor: Rakhee Gupte
-
Patent number: 10195248Abstract: Provided is a method for promoting wound healing, which comprises: administering a haptoglobin subunit to a subject in need thereof. Also provided is a method for promoting wound healing, which comprises: administering a modified haptoglobin subunit to a subject in need thereof, the modified haptoglobin subunit comprising an amino acid sequence selected from one of SEQ ID NOs: 1-3.Type: GrantFiled: December 7, 2016Date of Patent: February 5, 2019Assignee: TAIPEI MEDICAL UNIVERSITYInventors: Tsai-Mu Cheng, Che-Chang Chang, TH Alexander Wu
-
Patent number: 10188700Abstract: Provided is a method for promotion of angiogenesis, comprising: administering a haptoglobin subunit to a subject in need thereof. Also provided is a method for treating a disease related to defective angiogenesis, comprising: administering a haptoglobin subunit to a subject in need thereof. Further provided is a method for promotion of angiogenesis, comprising: administering a modified haptoglobin subunit to a subject in need thereof, the modified haptoglobin subunit comprising an amino acid sequence selected from one of SEQ ID NOs: 1-3. Additionally provided is a method for treating a disease related to defective angiogenesis, comprising: administering a modified haptoglobin subunit to a subject in need thereof, the modified haptoglobin subunit comprising an amino acid sequence selected from one of SEQ ID NOs: 1-3.Type: GrantFiled: December 7, 2016Date of Patent: January 29, 2019Assignee: TAIPEI MEDICAL UNIVERSITYInventors: Tsai-Mu Cheng, Che-Chang Chang
-
Patent number: 10144764Abstract: The present invention is directed to a novel class of antimicrobial agents called ?-AApeptides. The current invention provides various categories of ?-AApeptides, for example, linear ?-AApeptides, cyclic ?-AApeptides, and lipidated ?-AApeptides. ?-AApeptides of the current invention are designed to exert antimicrobial activity while being stable and non-toxic. ?-AApeptides also do not appear to lead to the development of microbial resistance in treated microorganisms. Thus, the disclosed ?-AApeptides can be used for the treatment of various medical conditions associated with pathogenic microorganisms.Type: GrantFiled: October 13, 2016Date of Patent: December 4, 2018Assignee: University of South FloridaInventors: Jianfeng Cai, Youhong Niu, Haifan Wu, Shruti Padhee
-
Patent number: 10081668Abstract: Disclosed are modified pigment epithelium-derived factor (PEDF) peptides, particulate carrier prodrugs thereof, and pharmaceutical compositions comprising the peptides or particulate carrier prodrugs. The peptides, particulate carrier prodrugs, and pharmaceutical compositions may be used to treat diseases and disorders that are amenable to treatment with anti-angiogenic agents, anti-tumorigenic agents, anti-fibrotic agents, chemotherapy-protecting agents, and immune stimulating agents.Type: GrantFiled: April 26, 2017Date of Patent: September 25, 2018Assignees: Northwestern University, Board of Regents of the University of NebraskaInventors: Jack Henkin, Olga Volpert, Serguei Vinogradov, Ignacio Melgar-Asensio
-
Patent number: 10060934Abstract: A method for screening a patient for angioinhibition resistance and treating said patient having a disease susceptible to treatment via an anti-angiogenic agent. The screening method includes an assay for identifying the presence of angioinhibition resistance in patients by collecting patient blood or serum and subjecting it to a Chick Chorioallantoic Membrane (CAM) angiogenesis assay configured for accepting a human tumor wherein the human tumor xenograft includes a vasculature system. The screening method and assay further includes steps that include using the CAM results for identifying the endogenous pro-angiogenic non-peptide hormone concentrations of the blood sample by calculating the vascular activity of the vasculature system of the human tumor xenograft in the presence of anti-angiogenic drugs and inducing in the patient, a state of subclinical hypothyroidism prior to commencing anti-angiogenic treatment.Type: GrantFiled: November 18, 2014Date of Patent: August 28, 2018Assignee: NANOPHARMACEUTICALS LLCInventors: Shaker A. Mousa, Paul J. Davis
-
Patent number: 9865053Abstract: The disclosure concerns a method for extracting geographic distribution statistics from patient tissue samples assayed with a tissue-based test for the purpose of scoring the patient tissue samples and guiding treatment based on the score(s). The method described herein utilizes digital image analysis of an image of one or more tissue sections to extract object-based (e.g., cells) features to generate a data array representing said tissue numerically in image analysis feature space. The numerical representation of the image of the tissue section in image analysis feature space is further processed using one or more algorithm processes to extract sophisticated geographical distribution features of one or more object type or sub-type in the tissue. Statistics describing the geographic distribution features are summarized to generate a patient-specific diagnostic score, and this score can be evaluated to guide patient treatment decisions.Type: GrantFiled: June 13, 2016Date of Patent: January 9, 2018Assignee: Flagship Biosciences, Inc.Inventors: Joshua C. Black, Logan Jerome Cerkovnik, Famke Aeffner, Nathan T. Martin, Joseph Krueger, Holger Lange
-
Patent number: 9821071Abstract: This disclosure relates to conjugates for targeting bacteria and related uses. In certain embodiments, the disclosure relates to methods of transferring a molecule of interest into bacteria comprising mixing bacteria with a non-naturally occurring conjugate under conditions such that the conjugate is transported across the bacterial cell wall. Typically, the conjugate comprises an oligosaccharide and a molecule of interest. In certain embodiments, the molecule of interest may be a tracer or an antibiotic.Type: GrantFiled: February 26, 2014Date of Patent: November 21, 2017Assignees: Emory University, Georgia Tech Research Corporation, Georgia State University Research Foundation, Inc.Inventors: Niren Murthy, Eric Seth Gilbert, Xinghai Ning, Mark Goodman, Bryan Stubblefield
-
Patent number: 9801921Abstract: The present application relates to the use of a pertussis toxin, and its derivatives, analogs, salts and pharmaceutical equivalents. In one embodiment, the invention provides a method of treating an autoimmune disease by administering pertussis toxin to the individual. In another embodiment, the autoimmune disease is multiple sclerosis. In another embodiment, the invention provides a method of treating a neurodegenerative disease such as Alzheimer's disease or Parkinson's disease by administering pertussis toxin, or a derivative, analog, salt or pharmaceutical equivalent.Type: GrantFiled: June 29, 2012Date of Patent: October 31, 2017Assignee: DIGNITY HEALTHInventor: Jiong Shi
-
Patent number: 9765116Abstract: Eph A receptor inhibitor peptides, and particularly Eph A4 receptor inhibitor peptides, are provided. The peptides comprise a sequence derived from the G-H loop of ephrin A4. Further, pharmaceutical compositions comprising said peptides and use thereof in treating, ameliorating or preventing diseases associated with memory formation are provided.Type: GrantFiled: April 13, 2014Date of Patent: September 19, 2017Assignee: CARMEL HAIFA UNIVERSITY ECONOMIC CORPORATION LTD.Inventors: Raphael Lemprecht, Monica Dines
-
Patent number: 9739766Abstract: The present invention relates to a cell model for diseases associated with corneal neovascularization by using Epstein Barr virus (EBV)-infected human corneal epithelial cells (HCECs). Provided are a method for preparing a cell model for diseases associated with corneal neovascularization by using EBV-infected HCECs, the method including: infecting HCECs with EBV; culturing the infected HCECs; and determining whether the cultured HCECs are infected with EBV. In addition, provided is a method for screening diseases associated with corneal neovascularization prepared by the cell model for diseases associated with corneal neovascularization.Type: GrantFiled: December 18, 2013Date of Patent: August 22, 2017Assignee: INJE UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Dae Young Hur, Ga Bin Park, Yeong Seok Kim, Dae Jin Kim, Seong Han Kim, Hyun Kyung Lee, Jae Wook Yang
-
Patent number: 9730891Abstract: The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.Type: GrantFiled: October 9, 2015Date of Patent: August 15, 2017Assignee: IPSEN BIOPHARM LTD.Inventors: Keelung Hong, Daryl C. Drummond, Dmitri Kirpotin
-
Patent number: 9724303Abstract: The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.Type: GrantFiled: December 10, 2015Date of Patent: August 8, 2017Assignee: IPSEN BIOPHARM LTD.Inventors: Keelung Hong, Daryl C. Drummond, Dmitri Kirpotin
-
Patent number: 9675665Abstract: A method of treating or preventing a gum disease or gum disorder or gum injury in a mammal by administering to the mammal at least one inflammation modulatory or anti-inflammatory protein or polypeptide, such as TSG-6 protein, or a biologically active fragment, derivative, or analogue thereof. Gum diseases or gum disorders or gum injuries that may be treated include periodontal gum disease, and gum wounds resulting from gum surgeries.Type: GrantFiled: December 10, 2014Date of Patent: June 13, 2017Assignee: The Texas A & M University SystemInventors: Darwin J. Prockop, Kathy K. H. Svoboda, Stacy Renay Beltran
-
Patent number: 9617311Abstract: Disclosed herein is a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues. The synthetic peptide has at least 80% amino acid sequence identity to SEQ ID NO: 1, and includes at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1. Also disclosed herein are compositions containing the synthetic peptide and applications thereof. According to various embodiments of the present disclosure, the synthetic peptide is useful in promoting stem cells proliferation or wound healing.Type: GrantFiled: March 12, 2015Date of Patent: April 11, 2017Assignee: Mackay Memorial HospitalInventors: Yeou-Ping Tsao, Tsung-Chuan Ho
-
Patent number: 9504729Abstract: Methods of inhibiting undesired angiogenesis are provided, which methods include administering to a subject a therapeutically effective amount of at least one of the compounds described herein, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: October 13, 2015Date of Patent: November 29, 2016Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Enrique Zudaire, Marta Aparicio, Frank Cuttitta
-
Patent number: 9416161Abstract: The present disclosure relates to protein and peptide chemistry. More particularly, it relates to compounds, compositions and uses thereof for promoting and inhibiting angiogenesis. The peptides of the present disclosure include peptides comprising SEQ ID NOs: 1-4 which promote angiogenesis and cell proliferation. Further, the anti-angiogenic compounds of the present disclosure include antisense oligonucleotides that hybridize or are complementary to the polynucleotides of SEQ ID NOs: 5-16, and the like.Type: GrantFiled: January 24, 2014Date of Patent: August 16, 2016Assignee: TRUSTEES OF TUFTS COLLEGEInventor: Ira M. Herman
-
Patent number: 9254309Abstract: A method for treating disorders involving deregulation of cell proliferation and/or angiogenesis comprising the administration of an effective amount of a multivalent synthetic compound comprising a support on which at least 3 pseudopeptide units are grafted, said compound being of formula (I).Type: GrantFiled: June 26, 2013Date of Patent: February 9, 2016Assignee: Centre National De La Recherche Scientifique (CNRS)Inventors: Jose Courty, Ara Hovanessian, Jean Paul Briand, Gilles Guichard, Yamina Hamma
-
Patent number: 9102720Abstract: The invention provides VEGF-C antagonists, such as anti-VEGF-C antibodies, and their use in the prevention and treatment of tumor progression.Type: GrantFiled: June 17, 2013Date of Patent: August 11, 2015Assignee: Genentech, Inc.Inventors: Anil D. Bagri, Germaine Fuh, Chingwei V. Lee
-
Patent number: 9090707Abstract: Described have herein are peptide analogs of a prominin-1 peptide, DRVQRQTTTVVA (SEQ. ID. NO:1) which have enhanced regenerative and/or angiogenesis activity, increase VEGF binding to endothelial cells, and/or increase wound healing activity relative to the peptide of SEQ ID NO: 1. Provided herein are fusion proteins and compositions comprising these pep tide analogs and uses thereof.Type: GrantFiled: January 27, 2011Date of Patent: July 28, 2015Assignee: Children's Medical Center CorporationInventors: Avner Adini, Robert D'Amato
-
Publication number: 20150141340Abstract: The present invention provides methods for inhibiting ocular angiogenesis, vascular leakage, and/or edema. The methods comprise administering to a subject an agent comprising a caveolin scaffolding domain. The present invention further encompasses methods of treating and/or preventing ophthalmic conditions that are associated with ocular angiogenesis, vascular leakage, or edema.Type: ApplicationFiled: May 30, 2013Publication date: May 21, 2015Inventor: William C. Sessa
-
Publication number: 20150133385Abstract: Peptide compounds derived from human melanotransferrin, and compositions thereof, are described. Uses of these peptide compounds, for example to modulate angiogenesis and/or cell migration, and/or to treat angiogenesis-related disorders (e.g., cancer), are also described.Type: ApplicationFiled: October 18, 2012Publication date: May 14, 2015Inventors: Richard BĂ©liveau, Jonathan Michaud-Levesque, Krishna G. Peri, Abdelkrim Habi, Nathalie Bousquet-Gagnon
-
Publication number: 20150132321Abstract: The present invention relates to methods of inhibiting capillary endothelial (CE) cell migration, the formation of CE networks and angiogenesis, and uses thereof for the purpose of treating angiogenesis-related diseases and disorders, particularly when the diseases or disorders are directly related aberrant angiogenesis. Inhibition is achieved by inhibiting TRPV4 activity, such as the levels of TRPV4 expression, calcium influx through TRPV4, and/or the intracellular signaling from TRPV4 via ?1 integrin activation.Type: ApplicationFiled: November 7, 2014Publication date: May 14, 2015Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Donald E. Ingber, Charles K. Thodeti
-
Patent number: 9023799Abstract: A method to treat the chronic stage of heart injury after ischemia or reperfusion by administering Midkine to a subject in need of such treatment is described.Type: GrantFiled: December 6, 2005Date of Patent: May 5, 2015Assignee: Cellmid LimitedInventors: Mitsuru Horiba, Itsuo Kodama, Takashi Muramatsu, Kenji Kadomatsu
-
Patent number: 9023795Abstract: Provided is a polypeptide having angiogenesis inhibiting activity. The polypeptide is derived from Placenta Growth Factor-1. Also provided are a derivative polypeptide of the polypeptide, a preparation method for polypeptide, and a pharmaceutical composition containing the polypeptide.Type: GrantFiled: July 1, 2011Date of Patent: May 5, 2015Assignee: Shanghai First People's HospitalInventors: Xun Xu, Ying Zheng, Hui Zhao
-
Publication number: 20150119330Abstract: Inhibitors of fibroblast activation protein alpha (FAP) and Prolyl Oligopeptidase (POP) are disclosed, along with their use in various therapies related to conditions, diseases, and disorders involving abnormal cell proliferation such as malignancies and angiogenesis, and in neural disorders such as Alzheimer's disease. Stalk portions of the inhibitor molecules, and substrates of FAP and POP, are also disclosed and may be used, for example, in screening methods for identifying such inhibitors.Type: ApplicationFiled: May 3, 2013Publication date: April 30, 2015Inventors: Patrick A. McGee, Kenneth W. Jackson, Victoria J. Christiansen
-
Publication number: 20150119329Abstract: The present invention is directed to a composition for the treatment or prevention of cerebral malaria that comprises an angiotensin receptor type-2 agonist and an antimalaria drug. The present invention is further directed to methods for treating and preventing cerebral malaria that involve administering an angiotensin receptor type-2 agonist and/or an angiotensin receptor type-1 antagonist.Type: ApplicationFiled: April 16, 2013Publication date: April 30, 2015Applicant: NEW YORK UNIVERSITYInventors: Ana Maria Rodriguez Fernandez, Julio Gallego-Delgado
-
Publication number: 20150111827Abstract: Provided is a polypeptide having angiogenesis inhibiting activity. The polypeptide is derived from Placenta Growth Factor-1. Also provided are a derivative polypeptide of the polypeptide, a preparation method for polypeptide, and a pharmaceutical composition containing the polypeptide.Type: ApplicationFiled: October 29, 2012Publication date: April 23, 2015Inventors: Xun Xu, Ying Zheng
-
Publication number: 20150093375Abstract: The present invention provides methods of using TSPAN12 and Norrin antagonists to inhibit ocular vascular development and to treat related disorders.Type: ApplicationFiled: April 25, 2014Publication date: April 2, 2015Applicant: GENENTECH, INC.Inventors: Harald J. JUNGE, Weilan YE
-
Publication number: 20150087589Abstract: Disclosed is a panel of biomarkers associated with angiogenesis, and the use of such biomarkers (genes, proteins, homologues and analogs thereof) to regulate angiogenesis. Methods for identifying compounds useful for regulating angiogenesis and conditions related thereto are disclosed.Type: ApplicationFiled: December 6, 2013Publication date: March 26, 2015Applicant: National Jewish HealthInventors: William P. Schiemann, Allan R. Albig
-
Publication number: 20150079094Abstract: The invention provides compositions and methods relating to bioactive peptide analogs of PEDF.Type: ApplicationFiled: September 12, 2014Publication date: March 19, 2015Inventors: Joyce Tombran-Tink, Colin J. Barnstable
-
Patent number: 8980268Abstract: The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Ang-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Ang-2 biological activities including angiogenesis.Type: GrantFiled: January 23, 2013Date of Patent: March 17, 2015Assignee: Regeneron Pharamceuticals, Inc.Inventors: Israel Lowy, Gavin Thurston, Christopher Daly
-
Patent number: 8975229Abstract: The present invention provides novel pharmaceutical agents and methods for treating or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy). The present invention provides pharmaceutical compositions and vaccines for treating and/or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy), comprising at least one type each of a peptide comprising an amino acid sequence derived from a VEGFR-1 protein and having an activity of inducing cytotoxic T cells, and a peptide comprising an amino acid sequence derived from a VEGFR-2 protein and having an activity of inducing cytotoxic T cells.Type: GrantFiled: June 10, 2010Date of Patent: March 10, 2015Assignee: OncoTherapy Science, Inc.Inventors: Motokazu Tsujikawa, Yusuke Nakamura, Takuya Tsunoda